Omega-3 world map: 2024 update

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Autoren

Externe Organisationen

  • Fatty Acid Research Institute (FARI)
  • University of Ottawa
  • Global Organization for EPA and DHA Omega-3s (GOED)
  • University of Waterloo
  • University of South Dakota
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Aufsatznummer101286
FachzeitschriftProgress in lipid research
Jahrgang95
Frühes Online-Datum13 Juni 2024
PublikationsstatusVeröffentlicht - Juli 2024

Abstract

In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I, in samples drawn after 1999. To convert the non-RBC-based EPA + DHA metrics into RBC we used newly developed equations. Baseline data from clinical trials and observational studies were acceptable. A literature search identified 328 studies meeting inclusion criteria encompassing 342,864 subjects from 48 countries/regions. Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low. Notable differences between the current and 2016 map were 1) USA, Canada, Italy, Turkey, UK, Ireland and Greece (moving from the very low to low category); 2) France, Spain and New Zealand (low to moderate); and 3) Finland and Iceland (moderate to desirable). Countries such as Iran, Egypt, and India exhibited particularly poor O3I levels.

ASJC Scopus Sachgebiete

  • Biochemie, Genetik und Molekularbiologie (insg.)
  • Biochemie
  • Biochemie, Genetik und Molekularbiologie (insg.)
  • Zellbiologie

Zitieren

Omega-3 world map: 2024 update. / Schuchardt, Jan Philipp; Beinhorn, Philine; Hu, Xue Feng et al.
in: Progress in lipid research, Jahrgang 95, 101286, 07.2024.

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Schuchardt, JP, Beinhorn, P, Hu, XF, Chan, HM, Roke, K, Bernasconi, A, Hahn, A, Sala-Vila, A, Stark, KD & Harris, WS 2024, 'Omega-3 world map: 2024 update', Progress in lipid research, Jg. 95, 101286. https://doi.org/10.1016/j.plipres.2024.101286
Schuchardt, J. P., Beinhorn, P., Hu, X. F., Chan, H. M., Roke, K., Bernasconi, A., Hahn, A., Sala-Vila, A., Stark, K. D., & Harris, W. S. (2024). Omega-3 world map: 2024 update. Progress in lipid research, 95, Artikel 101286. https://doi.org/10.1016/j.plipres.2024.101286
Schuchardt JP, Beinhorn P, Hu XF, Chan HM, Roke K, Bernasconi A et al. Omega-3 world map: 2024 update. Progress in lipid research. 2024 Jul;95:101286. Epub 2024 Jun 13. doi: 10.1016/j.plipres.2024.101286
Schuchardt, Jan Philipp ; Beinhorn, Philine ; Hu, Xue Feng et al. / Omega-3 world map : 2024 update. in: Progress in lipid research. 2024 ; Jahrgang 95.
Download
@article{46a2d8bba5ba47e8b20dc8a8867b877b,
title = "Omega-3 world map: 2024 update",
abstract = "In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I, in samples drawn after 1999. To convert the non-RBC-based EPA + DHA metrics into RBC we used newly developed equations. Baseline data from clinical trials and observational studies were acceptable. A literature search identified 328 studies meeting inclusion criteria encompassing 342,864 subjects from 48 countries/regions. Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low. Notable differences between the current and 2016 map were 1) USA, Canada, Italy, Turkey, UK, Ireland and Greece (moving from the very low to low category); 2) France, Spain and New Zealand (low to moderate); and 3) Finland and Iceland (moderate to desirable). Countries such as Iran, Egypt, and India exhibited particularly poor O3I levels.",
keywords = "Conversion equation, DHA, EPA, Estimated Omega-3 Index, Global omega-3 status, GOED clinical database",
author = "Schuchardt, {Jan Philipp} and Philine Beinhorn and Hu, {Xue Feng} and Chan, {Hing Man} and Kaitlin Roke and Aldo Bernasconi and Andreas Hahn and Aleix Sala-Vila and Stark, {Ken D} and Harris, {William S}",
note = "Copyright {\textcopyright} 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.",
year = "2024",
month = jul,
doi = "10.1016/j.plipres.2024.101286",
language = "English",
volume = "95",
journal = "Progress in lipid research",
issn = "0079-6832",
publisher = "Elsevier Ltd.",

}

Download

TY - JOUR

T1 - Omega-3 world map

T2 - 2024 update

AU - Schuchardt, Jan Philipp

AU - Beinhorn, Philine

AU - Hu, Xue Feng

AU - Chan, Hing Man

AU - Roke, Kaitlin

AU - Bernasconi, Aldo

AU - Hahn, Andreas

AU - Sala-Vila, Aleix

AU - Stark, Ken D

AU - Harris, William S

N1 - Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2024/7

Y1 - 2024/7

N2 - In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I, in samples drawn after 1999. To convert the non-RBC-based EPA + DHA metrics into RBC we used newly developed equations. Baseline data from clinical trials and observational studies were acceptable. A literature search identified 328 studies meeting inclusion criteria encompassing 342,864 subjects from 48 countries/regions. Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low. Notable differences between the current and 2016 map were 1) USA, Canada, Italy, Turkey, UK, Ireland and Greece (moving from the very low to low category); 2) France, Spain and New Zealand (low to moderate); and 3) Finland and Iceland (moderate to desirable). Countries such as Iran, Egypt, and India exhibited particularly poor O3I levels.

AB - In 2016, the first worldwide n3 PUFA status map was published using the Omega-3 Index (O3I) as standard biomarker. The O3I is defined as the percentage of EPA + DHA in red blood cell (RBC) membrane FAs. The purpose of the present study was to update the 2016 map with new data. In order to be included, studies had to report O3I and/or blood EPA + DHA levels in metrics convertible into an estimated O3I, in samples drawn after 1999. To convert the non-RBC-based EPA + DHA metrics into RBC we used newly developed equations. Baseline data from clinical trials and observational studies were acceptable. A literature search identified 328 studies meeting inclusion criteria encompassing 342,864 subjects from 48 countries/regions. Weighted mean country O3I levels were categorized into very low ≤4%, low >4-6%, moderate >6-8%, and desirable >8%. We found that the O3I in most countries was low to very low. Notable differences between the current and 2016 map were 1) USA, Canada, Italy, Turkey, UK, Ireland and Greece (moving from the very low to low category); 2) France, Spain and New Zealand (low to moderate); and 3) Finland and Iceland (moderate to desirable). Countries such as Iran, Egypt, and India exhibited particularly poor O3I levels.

KW - Conversion equation

KW - DHA

KW - EPA

KW - Estimated Omega-3 Index

KW - Global omega-3 status

KW - GOED clinical database

UR - http://www.scopus.com/inward/record.url?scp=85197247011&partnerID=8YFLogxK

U2 - 10.1016/j.plipres.2024.101286

DO - 10.1016/j.plipres.2024.101286

M3 - Review article

C2 - 38879135

VL - 95

JO - Progress in lipid research

JF - Progress in lipid research

SN - 0079-6832

M1 - 101286

ER -

Von denselben Autoren